Savient Pharmaceuticals Inc Watch

from S-3ASR 33 pages Savient Pharmaceuticals, Inc. [—]% Convertible Senior Notes Due [February 1], 20[18] Underwriting Agreement

from 8-K 32 pages Savient Pharmaceuticals, Inc. 4,300,000 Shares of Common Stock, $.01 Per Share Par Value Underwriting Agreement

from 8-K 41 pages 5,927,343 Units Savient Pharmaceuticals, Inc. Placement Agent Agreement

from SC 13G/A 1 page Exhibit 1.1 Joint Filing Agreement the Undersigned Hereby Agree That the Statement on This Schedule 13g/A, Dated Febraury 14, 2003, (The "Schedule 13g/A"), With Respect to the Common Stock, $.01 Par Value, of Bio-Technology General Corp. Is Filed on Behalf of Each of US Pursuant to and in Accordance With the Provisions of Rule 13d-1(k) Under the Securities and Exchange Act of 1934, as Amended, and That This Agreement Shall Be Included as an Exhibit to This Schedule 13g/A. Each of the Undersigned Agrees to Be Responsible for the Timely Filing of the Schedule 13g/A, and for the Completeness and Accuracy of the Information Concerning Itself Contained Therein. This Agreement May Be Executed in Any Number of Counterparts, All of Which Taken Together Shall Constitute One and the Same Instrument. in Witness Whereof, the Undersigned Have Executed This Agreement as of the 14th Day of February, 2003. Orbimed Advisors Inc. By: /S/ Samuel D. Isaly Name: Samuel D. Isaly Title: President Orbimed Advisors LLC By: /S/ Samuel D. Isaly Name: Samuel D. Isaly Title: President of Managing Member, Orbimed Advisors Inc. Orbimed Capital LLC By: /S/ Samuel D. Isaly Name: Samuel D. Isaly Title: Managing Member By: /S/ Samuel D. Isaly Name: Samuel D. Isaly